BR0312399A - Composição destinada ao tratamento ou à profilaxia de uma patologia ligada à inflamação, à neurodegenerescência, à desregularização do metabolismo lipìdico e/ou glicìdico, à proliferação e/ou à diferenciação celular e/ou ao envelhecimento cutâneo ou do sistema nervoso central, e, utilização de um composto - Google Patents

Composição destinada ao tratamento ou à profilaxia de uma patologia ligada à inflamação, à neurodegenerescência, à desregularização do metabolismo lipìdico e/ou glicìdico, à proliferação e/ou à diferenciação celular e/ou ao envelhecimento cutâneo ou do sistema nervoso central, e, utilização de um composto

Info

Publication number
BR0312399A
BR0312399A BR0312399-5A BR0312399A BR0312399A BR 0312399 A BR0312399 A BR 0312399A BR 0312399 A BR0312399 A BR 0312399A BR 0312399 A BR0312399 A BR 0312399A
Authority
BR
Brazil
Prior art keywords
proliferation
inflammation
compound
treatment
composition
Prior art date
Application number
BR0312399-5A
Other languages
English (en)
Other versions
BRPI0312399B1 (pt
BRPI0312399B8 (pt
Inventor
Jamila Najib
Karine Caumont-Bertrand
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of BR0312399A publication Critical patent/BR0312399A/pt
Publication of BRPI0312399B1 publication Critical patent/BRPI0312399B1/pt
Publication of BRPI0312399B8 publication Critical patent/BRPI0312399B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSIçãO DESTINADA AO TRATAMENTO OU à PROFILAXIA DE UMA PATOLOGIA LIGADA A INFLAMAçãO, A NEURODEGENERESCêNCIA, à DESREGULARIZAçãO DO METABOLISMO LIPìDICO E/OU GLICìDICO, à PROLIFERAçãO E/OU à DIFERENCIAçãO CELULAR E/OU AO ENVELHECIMENTO CUTâNEO OU DO SISTEMA NERVOSO CENTRAL, E, UTILIZAçãO DE UM COMPOSTO". A presente invenção refere-se a composições dos derivados 1,3-difenilprop-2-en-1-ona substituídos destinados a um uso terapêutico. As composições da invenção são utilizáveis notadamente para prevenir ou tratar as doenças cardiovasculares, a sindrome X, a restenose, o diabetes, a obesidade, a hipertensão, as doenças inflamatórias, os cânceres ou neoplasmas (tumores benignos ou malignos), as doenças neurodegenerativas, dermatologias e os distúrbios ligados ao estresse oxidativo, para prevenir ou tratar os efeitos do envelhecimento em geral e por exemplo o envelhecimento cutâneo, notadamente no domínio cosmético (surgimento de rugas, etc.).
BRPI0312399A 2002-07-08 2003-07-08 composição destinada ao tratamento ou à profilaxia de uma patologia ligada à inflamação, à neurodegenerescência, à desregularização do metabolismo lipídico e/ou glicídico, à proliferação e/ou à diferenciação celular e/ou ao envelhecimento cutâneo ou do sistema nervoso central BRPI0312399B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR02/08570 2002-07-08
FR0208570A FR2841784B1 (fr) 2002-07-08 2002-07-08 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
PCT/FR2003/002128 WO2004005243A2 (fr) 2002-07-08 2003-07-08 Composition a base de derives de 1,3-diphenylprop-2-en-one substitues

Publications (3)

Publication Number Publication Date
BR0312399A true BR0312399A (pt) 2005-04-12
BRPI0312399B1 BRPI0312399B1 (pt) 2020-03-31
BRPI0312399B8 BRPI0312399B8 (pt) 2021-05-25

Family

ID=29725282

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312399A BRPI0312399B8 (pt) 2002-07-08 2003-07-08 composição destinada ao tratamento ou à profilaxia de uma patologia ligada à inflamação, à neurodegenerescência, à desregularização do metabolismo lipídico e/ou glicídico, à proliferação e/ou à diferenciação celular e/ou ao envelhecimento cutâneo ou do sistema nervoso central

Country Status (24)

Country Link
US (3) US7632870B2 (pt)
EP (1) EP1519908B1 (pt)
JP (1) JP4907083B2 (pt)
KR (1) KR100947907B1 (pt)
CN (1) CN1688532B (pt)
AT (1) ATE364588T1 (pt)
AU (1) AU2003264699B2 (pt)
BR (1) BRPI0312399B8 (pt)
CA (1) CA2490993C (pt)
CY (1) CY1108051T1 (pt)
DE (1) DE60314420T2 (pt)
DK (1) DK1519908T3 (pt)
EA (1) EA012699B1 (pt)
ES (1) ES2287529T3 (pt)
FR (1) FR2841784B1 (pt)
IL (1) IL165454A (pt)
MX (1) MXPA05000425A (pt)
NO (1) NO334650B1 (pt)
NZ (1) NZ538052A (pt)
PL (1) PL207707B1 (pt)
PT (1) PT1519908E (pt)
SI (1) SI1519908T1 (pt)
WO (1) WO2004005243A2 (pt)
ZA (1) ZA200501081B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
US7547729B2 (en) * 2004-01-08 2009-06-16 Genfit 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
JP5380069B2 (ja) 2005-03-11 2014-01-08 ハワード フローリー インスティチュート フラボノイド化合物およびその使用
MX2012006062A (es) 2009-11-26 2012-06-28 Genfit Uso de derivados de 1,3-difenilprop-2-en-1-ona para el tratamiento de trastornos hepaticos.
WO2011080276A1 (en) 2009-12-29 2011-07-07 Genfit Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
JP5593445B2 (ja) * 2010-07-12 2014-09-24 エフ．ホフマン−ラ ロシュ アーゲー １−ヒドロキシイミノ−３−フェニル−プロパン類
CN103889411B (zh) 2011-07-15 2018-03-16 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
RU2014119220A (ru) * 2011-10-26 2015-12-10 Ф. Хоффманн-Ля Рош Аг 1-циклоалкил-или 1-гетероциклил-гидроксиимино-3-фенилпропаны
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
MX2015006023A (es) 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
MX361565B (es) * 2013-01-18 2018-12-11 Genfit Metodos de tratamiento de fibrosis y canceres.
WO2014152016A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
SG11201607075TA (en) 2014-02-27 2016-09-29 Nusirt Sciences Inc Compositions and methods for the reduction or prevention of hepatic steatosis
EP3416629A4 (en) 2016-02-16 2019-08-07 CoNCERT Pharmaceuticals, Inc. DEUTERATED GFT-505
JP7418959B2 (ja) * 2016-03-30 2024-01-22 ジェンフィ 非アルコール性脂肪性肝炎の非侵襲的診断
WO2017181162A1 (en) * 2016-04-16 2017-10-19 University Of Florida Research Foundation, Incorporated Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus
CN108658908B (zh) 2017-07-31 2019-05-10 广州必贝特医药技术有限公司 1，3-二取代烯酮类化合物及其应用
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
WO2019105234A1 (zh) 2017-11-30 2019-06-06 四川科伦博泰生物医药股份有限公司 芳香族化合物及其药物组合物和用途
EP3830070A1 (en) 2018-08-03 2021-06-09 Genfit Elafibranor salts
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
MX2022009778A (es) 2020-02-10 2022-09-09 Genfit Polimorfos de elafibranor.
WO2024029639A1 (ko) * 2022-08-02 2024-02-08 제이투에이치바이오텍 주식회사 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558612A (en) * 1968-05-22 1971-01-26 Dow Chemical Co Substituted phenoxyacetic acids
CH593224A5 (pt) * 1973-10-30 1977-11-30 Taisho Pharmaceutical Co Ltd
US3994955A (en) * 1975-01-20 1976-11-30 G. D. Searle & Co. Substituted phenoxydialkylacetic acids and esters
JPS5278856A (en) * 1975-12-26 1977-07-02 Taisho Pharmaceut Co Ltd Preparation of chalcone ethers
US4190671A (en) * 1977-03-17 1980-02-26 Biorex Laboratories Limited Chalcone derivatives
JPS5419947A (en) * 1977-07-16 1979-02-15 Taisho Pharmaceut Co Ltd Chalcone derivatives
US4163859A (en) * 1977-07-18 1979-08-07 G. D. Searle & Co. Phenoxyldialkyl acetic acids and esters
GB8426424D0 (en) * 1984-10-19 1984-11-28 Biorex Laboratories Ltd Chalcone derivatives
JPS6310720A (ja) * 1986-07-01 1988-01-18 Nippon Kayaku Co Ltd ５−リポキシゲナ−ゼ阻害剤および抗アレルギ−剤
JPH023670A (ja) 1988-06-22 1990-01-09 Nippon Oil & Fats Co Ltd アルキルチオカルコン誘導体
JPH0742227B2 (ja) * 1988-11-25 1995-05-10 日本ハイポックス 腎臓疾患治療剤
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5705521A (en) * 1990-02-12 1998-01-06 The Center For Innovative Technology Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
JPH0442229A (ja) * 1990-06-08 1992-02-12 Fujitsu Ltd レジスト材料およびパターンの形成方法
JPH05255655A (ja) 1992-03-12 1993-10-05 Kanebo Ltd 紫外線吸収剤
JPH06122623A (ja) * 1992-10-09 1994-05-06 Minofuaagen Seiyaku Honpo:Goushi 抗腫瘍剤
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
DE4327365A1 (de) * 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
AU5474198A (en) 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
EP0947511A1 (en) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
CN1327384A (zh) * 1998-10-20 2001-12-19 韩国科学技术研究院 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮
AU2001228825A1 (en) * 2000-01-27 2001-08-07 Takara Bio Inc. Remedies
NZ523443A (en) 2000-06-20 2004-11-26 Atherogenics Inc 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
EP1254759B1 (de) 2001-05-03 2009-03-18 Leister Process Technologies Düse zum Schweissen von Kunststoffbahnen oder -folien
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one

Also Published As

Publication number Publication date
NZ538052A (en) 2007-09-28
FR2841784A1 (fr) 2004-01-09
WO2004005243A2 (fr) 2004-01-15
BRPI0312399B1 (pt) 2020-03-31
CY1108051T1 (el) 2013-09-04
US20050171149A1 (en) 2005-08-04
CN1688532A (zh) 2005-10-26
DE60314420T2 (de) 2008-02-28
BRPI0312399B8 (pt) 2021-05-25
PL207707B1 (pl) 2011-01-31
MXPA05000425A (es) 2005-07-22
PL373465A1 (en) 2005-09-05
EP1519908B1 (fr) 2007-06-13
SI1519908T1 (sl) 2007-08-31
US7632870B2 (en) 2009-12-15
AU2003264699A1 (en) 2004-01-23
JP2005532386A (ja) 2005-10-27
US8461212B2 (en) 2013-06-11
AU2003264699B2 (en) 2009-09-24
EP1519908A2 (fr) 2005-04-06
US20120129932A1 (en) 2012-05-24
ZA200501081B (en) 2007-04-25
EA200500170A1 (ru) 2005-10-27
KR20050019818A (ko) 2005-03-03
KR100947907B1 (ko) 2010-03-17
US8106097B2 (en) 2012-01-31
DK1519908T3 (da) 2007-10-15
NO334650B1 (no) 2014-05-05
JP4907083B2 (ja) 2012-03-28
PT1519908E (pt) 2007-09-04
DE60314420D1 (de) 2007-07-26
EA012699B1 (ru) 2009-12-30
IL165454A0 (en) 2006-01-15
WO2004005243A3 (fr) 2004-04-22
US20100120909A1 (en) 2010-05-13
FR2841784B1 (fr) 2007-03-02
CA2490993C (fr) 2012-09-18
IL165454A (en) 2012-12-31
NO20045082L (no) 2004-12-27
CN1688532B (zh) 2012-07-11
CA2490993A1 (fr) 2004-01-15
ES2287529T3 (es) 2007-12-16
ATE364588T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
BR0312399A (pt) Composição destinada ao tratamento ou à profilaxia de uma patologia ligada à inflamação, à neurodegenerescência, à desregularização do metabolismo lipìdico e/ou glicìdico, à proliferação e/ou à diferenciação celular e/ou ao envelhecimento cutâneo ou do sistema nervoso central, e, utilização de um composto
Contardi et al. Electrospun polyvinylpyrrolidone (PVP) hydrogels containing hydroxycinnamic acid derivatives as potential wound dressings
AU716131B2 (en) Genistein as a preventive against ultraviolet induced skin photodamage and cancer
Nahhas et al. The potential role of antioxidants in mitigating skin hyperpigmentation resulting from ultraviolet and visible light‐induced oxidative stress
Choi et al. Aloesin inhibits hyperpigmentation induced by UV radiation
Machiah et al. A glycoprotein from a folk medicinal plant, Withania somnifera, inhibits hyaluronidase activity of snake venoms
Heo et al. Phytochemical-induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis and differentiation in malignant melanoma cells
TR200102072T2 (tr) İltihap karşıtı maddeler olarak aromatik çok döngülü bileşimler
Fu et al. Fargesin inhibits melanin synthesis in murine malignant and immortalized melanocytes by regulating PKA/CREB and P38/MAPK signaling pathways
Garone et al. A review of common tanning methods
TR200102817T2 (tr) Antiinflamatuar ajanlar olarak faydalı bileşikler
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
Liang et al. Lycium barbarum polysaccharide protects HSF cells against ultraviolet-induced damage through the activation of Nrf2
Huang et al. Dihydromyricetin from Ampelopsis grossedentata inhibits melanogenesis through down-regulation of MAPK, PKA and PKC signaling pathways
Nakano et al. Anti-inflammatory effects of new catechin derivatives in a hapten-induced mouse contact dermatitis model
Ko et al. Norartocarpetin from a folk medicine Artocarpus communis plays a melanogenesis inhibitor without cytotoxicity in B16F10 cell and skin irritation in mice
GB2580725A (en) Anti-aging corrective and protective formulation and methods
Park et al. Protection against UVB-induced damages in human dermal fibroblasts: Efficacy of tricin isolated from enzyme-treated Zizania latifolia extract
Nandave et al. A pharmacological review on SIRT 1 and SIRT 2 proteins, activators, and inhibitors: Call for further research
Mani et al. Dopamine-mediated vanillin multicomponent derivative synthesis via grindstone method: application of antioxidant, anti-tyrosinase, and cytotoxic activities
NO20064753L (no) Kombinasjonsterapi
Li et al. Curcumin protects thymus against D-galactose-induced senescence in mice
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
CZ2005136A3 (cs) Oprava mutagenního poskození DNA
NO20055650L (no) Ruteinum (II)-komplekser for behandling av tumorer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07C 51/00 , C07C 67/00 , C07C 59/90 , C07C 59/88 , C07C 59/84 , C07C 69/712 , C07C 69/67 , C07C 251/48 , C07C 323/63 , C07C 281/00 , C07C 323/09 , C07D 311/30 , A61K 31/192 , A61K 31/216 , A61P 25/16 , A61P 25/28 , A61P 35/00 , A61P 37/08 , A61P 9/10 , A61P 3/04 ,A61P 3/08 , A61P 17/04 , A61P 17/06 , A61P 17/00 , A61P 11/06 , A61K 31/194

Ipc: A61K 31/05 (1974.07), A61K 31/055 (1974.07), A61K

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07C 51/00 , C07C 67/00 , C07C 59/90 , C07C 59/88 , C07C 59/84 , C07C 69/712 , C07C 69/67 , C07C 251/48 , C07C 323/63 , C07C 281/00 , C07C 323/09 , C07D 311/30 , A61K 31/192 , A61K 31/216 , A61P 25/16 , A61P 25/28 , A61P 35/00 , A61P 37/08 , A61P 9/10 , A61P 3/04 , A61P 3/08 , A61P 17/04 , A61P 17/06 , A61P 17/00 , A61P 11/06 , A61K 31/194

Ipc: A61K 31/05 (1974.07), A61K 31/055 (1974.07), A61K

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2782 DE 30/04/2024 POR TER SIDO INDEVIDA.